Cerebrospinal fluid abnormalities in a phase III trial of Avonex®(IFNβ-1a) for relapsing multiple sclerosis
RA Rudick, DL Cookfair, NA Simonian… - Journal of …, 1999 - Elsevier
Background and objective: This report provides results of CSF analyses done in a subset of
relapsing remitting MS patients participating in a placebo-controlled, double-blind, phase III
clinical trial of IFNβ-Studies supported by the National Multiple Sclerosis Society (grants
RG2019, RG2827), a (Avonex®, Biogen). The clinical trial demonstrated that IFNβ-1a
treatment resulted in significantly reduced disability progression, annual relapse rate, and
new brain lesions visualized by cranial magnetic resonance imaging. The objectives of the …
relapsing remitting MS patients participating in a placebo-controlled, double-blind, phase III
clinical trial of IFNβ-Studies supported by the National Multiple Sclerosis Society (grants
RG2019, RG2827), a (Avonex®, Biogen). The clinical trial demonstrated that IFNβ-1a
treatment resulted in significantly reduced disability progression, annual relapse rate, and
new brain lesions visualized by cranial magnetic resonance imaging. The objectives of the …